SKIN SkinHealth Systems Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1818093 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-4.4%
TTM net income YoY-55.7%
TTM EPS YoY117.5%
Revenue 3-yr CAGR-10.3%
Net income 3-yr CAGR—
Margins
Gross margin67.2%
Operating margin2.4%
Net margin-6.3%
FCF margin7.9%
EBITDA margin3.2%
Returns
ROE-30.1%
ROA-4.1%
ROIC (approx.)7.1%
Asset turnover0.65x
Leverage & solvency
Liabilities / assets85.7%
Debt / equity0.00x
Current ratio2.89x
Interest coverage0.27x
Cash quality & payout
Operating cash flow / net income-1.29x
Accruals ratio-9.4%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $300.79M | $334.29M |
| Cost of revenue | $104.43M | $152.00M |
| Gross profit | $196.36M | $182.30M |
| R&D expense | $5.63M | $6.30M |
| SG&A expense | $117.95M | $125.46M |
| Operating income | -$20.80M | -$67.77M |
| Interest expense | $19.33M | $10.41M |
| Pretax income | -$5.94M | -$29.55M |
| Income tax | $3.58M | -$452,000 |
| Net income | -$9.52M | -$29.10M |
| EBITDA | -$16.95M | -$57.83M |
| EPS (basic) | -0.08 | -0.23 |
| EPS (diluted) | -0.16 | -0.36 |
| Weighted avg. shares (diluted) | 135.80M | 142.49M |
| Balance sheet | ||
| Cash & equivalents | $232.67M | $370.06M |
| Receivables | $21.74M | $27.64M |
| Inventory | $48.01M | $69.11M |
| Current assets | $309.52M | $477.12M |
| PP&E, net | $2.54M | $5.98M |
| Goodwill | $126.62M | $123.50M |
| Intangibles | $35.76M | $47.51M |
| Total assets | $499.80M | $685.68M |
| Current liabilities | $186.28M | $68.15M |
| Long-term debt | — | $552.20M |
| Total debt | — | $552.20M |
| Total liabilities | $438.75M | $633.88M |
| Shareholders' equity | $61.06M | $51.80M |
| Net debt | — | $182.13M |
| Shares outstanding | 6.38M | 124.92M |
| Cash flow statement | ||
| Operating cash flow | $37.48M | $16.13M |
| Capital expenditure | $303,000 | $756,000 |
| Free cash flow | $37.18M | $15.38M |
| Investing cash flow | -$5.16M | -$6.79M |
| Financing cash flow | -$174.93M | -$158.34M |
| Depreciation & amortization | $3.85M | $9.94M |
| Stock-based compensation | $14.82M | $26.70M |
| Share buybacks | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.